We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva's Huntington Disease Drug Receives CRL from the FDA
Read MoreHide Full Article
Teva Pharmaceutical Industries Limited (TEVA - Free Report) suffered a regulatory setback with the FDA issuing a complete response letter (CRL) for the new drug application for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD).
In its CRL, the FDA has asked Teva to re-analyze blood levels of certain metabolites. Teva noted that these metabolites are not novel and are also observed in patients taking tetrabenazine or deutetrabenazine. Importantly, the regulatory agency did not ask the company to conduct additional studies.
Teva plans to work closely with the FDA to address the issue. A response to the CRL will be submitted in the third quarter of 2016.
Although the CRL on SD-809 comes as a disappointment for Teva, the most important thing is that the FDA has not asked the company for additional studies to be conducted, which would have delayed the candidate from entering the U.S. markets further.
Per the company’s press release, HD is a rare and fatal neurodegenerative disorder affecting approximately one in 7,000–10,000 people in western countries. While chorea is one of the most prominent physical manifestations of this disease, it occurs in roughly 90% of patients at some point in the course of their illness.
Notably, SD-809 is the first deuterated product to be reviewed by the FDA. Considering the lack of treatments for HD, its approval will be a huge boost for the patient population as well as for the company.
We note that SD-809 became a part of Teva’s pipeline following the May 2015 acquisition of Auspex Pharmaceuticals.
Apart from HD, Teva is also evaluating SD-809 for a couple of additional indications including treatment of patients with tardive dyskinesia (TD) and Tourette syndrome (TS). Currently, a phase III (AIM-TD) efficacy and safety study in patients with moderate-to-severe TD is in progress with additional data from the study anticipated later in 2016. The company is also planning to evaluate SD-809 for the treatment of tics associated with TS.
Teva is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Bristol-Myers Squibb Company (BMY - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva's Huntington Disease Drug Receives CRL from the FDA
Teva Pharmaceutical Industries Limited (TEVA - Free Report) suffered a regulatory setback with the FDA issuing a complete response letter (CRL) for the new drug application for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD).
In its CRL, the FDA has asked Teva to re-analyze blood levels of certain metabolites. Teva noted that these metabolites are not novel and are also observed in patients taking tetrabenazine or deutetrabenazine. Importantly, the regulatory agency did not ask the company to conduct additional studies.
Teva plans to work closely with the FDA to address the issue. A response to the CRL will be submitted in the third quarter of 2016.
Although the CRL on SD-809 comes as a disappointment for Teva, the most important thing is that the FDA has not asked the company for additional studies to be conducted, which would have delayed the candidate from entering the U.S. markets further.
Per the company’s press release, HD is a rare and fatal neurodegenerative disorder affecting approximately one in 7,000–10,000 people in western countries. While chorea is one of the most prominent physical manifestations of this disease, it occurs in roughly 90% of patients at some point in the course of their illness.
Notably, SD-809 is the first deuterated product to be reviewed by the FDA. Considering the lack of treatments for HD, its approval will be a huge boost for the patient population as well as for the company.
We note that SD-809 became a part of Teva’s pipeline following the May 2015 acquisition of Auspex Pharmaceuticals.
Apart from HD, Teva is also evaluating SD-809 for a couple of additional indications including treatment of patients with tardive dyskinesia (TD) and Tourette syndrome (TS). Currently, a phase III (AIM-TD) efficacy and safety study in patients with moderate-to-severe TD is in progress with additional data from the study anticipated later in 2016. The company is also planning to evaluate SD-809 for the treatment of tics associated with TS.
Teva is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Bristol-Myers Squibb Company (BMY - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>